FDA guidance
Additional Recommendations for Testing Whole Blood, Blood Components, Source Plasma and…
FDA guidance · Final · issued May 16, 1996
Key facts
| Title | Additional Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV): Memorandum to Registered Blood and Plasma Establishments |
|---|---|
| Status | Final |
| Issue date | May 16, 1996 |
| Center | Center for Biologics Evaluation and Research |
| Issuing office | Center for Biologics Evaluation and Research |
| Communication type | Memorandum |
| Regulated product | Biologics |
| Docket number | FDA-2022-D-0498 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents